Cleveland Clinic Taussig Cancer Institute

Taussig Cancer Institute is the hub for Cleveland Clinic Cancer Center.


 

2019 ASH Review on R/R DLBCL: For Frail Unfit Patients, Addition of Polatuzumab Vedotin to BR Is Tolerable and Improves ORR, CR, PFS and OS

117 views
April 14, 2020
0 Comments
Login to view comments. Click here to Login
Malignant Hematology